{"id":"W4288751769","doi":"10.1038/s41598-022-15552-5","title":"Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Division of Chemistry; Biocenter Finland; Ministero dello Sviluppo Economico; Genome Canada; Fundação de Amparo à Pesquisa do Estado de São Paulo; Ontario Ministry of Economic Development and Innovation; Wellcome Trust; Itä-Suomen Yliopisto; European Federation of Pharmaceutical Industries and Associations; Merck KGaA; Pfizer; University of North Carolina at Chapel Hill; Chordoma Foundation; Novartis Pharma; China Scholarship Council; National Science Foundation","keywords":"Gefitinib; Afatinib; Erlotinib; EGFR inhibitors; Epidermal growth factor receptor; Lapatinib; Cancer research; Scaffold; Chemistry; Biology; Receptor; Medicine; Biochemistry; Cancer; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00201679,0.0001847188,0.0002283973,0.0001236086,0.0007081864,0.00006920122,0.0002920329,0.0001364393,0.0002222944],"category_scores_gemma":[0.001334282,0.0001515235,0.0002608347,0.0004156439,0.0002071493,0.00002272535,0.0003759967,0.000137103,0.000001476683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007753316,"about_ca_system_score_gemma":0.0004083117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001167563,"about_ca_topic_score_gemma":0.000007183638,"domain_scores_codex":[0.9973986,0.0001552695,0.0008482689,0.00075424,0.0005096431,0.0003339529],"domain_scores_gemma":[0.9980437,0.000034176,0.0007973083,0.0006976264,0.0003399834,0.00008720686],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00008242363,0.0001296931,0.002750737,0.00003716918,0.00003394455,0.000003677856,0.00009538126,0.003847847,0.9793854,0.0002501878,0.01259022,0.0007933232],"study_design_scores_gemma":[0.0002990186,0.0002002168,0.00006656801,0.00001194916,0.00001464117,0.00007364872,0.0002323663,0.001497904,0.9637142,0.0003375493,0.03337348,0.0001784225],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879336,0.000165425,0.00207735,0.0003749037,0.007507961,0.001317438,0.00005522999,0.00002542476,0.0005426201],"genre_scores_gemma":[0.9930813,0.000004438529,0.003395822,0.0001395737,0.0002376445,0.000213053,0.0006206239,0.00003014868,0.002277439],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02078326,"threshold_uncertainty_score":0.6178951,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0175423633137492,"score_gpt":0.2566396367119733,"score_spread":0.2390972733982241,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}